Abrilumab

From WikiMD.org
Jump to navigation Jump to search

Abrilumab (pronounced as ab-ri-lu-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a type of biologic therapy that targets and inhibits the function of a specific protein in the body.

Etymology

The name "Abrilumab" is derived from the Latin word "abri", meaning "to open", and "lumab", a common suffix for monoclonal antibodies. This reflects the drug's mechanism of action, which involves opening up pathways in the immune system to reduce inflammation.

Mechanism of Action

Abrilumab works by binding to the alpha4-beta7 integrin, a protein found on the surface of certain immune cells. By blocking this protein, Abrilumab prevents these cells from migrating to areas of inflammation in the body, thereby reducing symptoms of autoimmune diseases.

Uses

Abrilumab is currently being investigated for use in several autoimmune diseases, including Ulcerative Colitis and Crohn's Disease. It has shown promise in early clinical trials, but further research is needed to confirm its efficacy and safety.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski